Opthea Reimagined
Opthea is leveraging its deep expertise
Opthea is relaunching with a focused operating model and a clear scientific strategy centred on OPT-302, a first-in-class VEGF-C/D ‘trap’ designed to target the abnormal lymphatic signaling and remodeling that contribute to the lung pathology of lymphangioleiomyomatosis (LAM).
LAM is an orphan disease that primarily affects women and is characterised by progressive cystic destruction of the lung and abnormal lymphatic remodeling. The disease can be devastating, leading to worsening respiratory impairment, loss of lung function, and profound impact on quality of life despite currently available therapies.
Our Science Based on Bold Innovation
Sozinibercept combination therapy has the potential to elevate the standard of care by delivering superior visual outcomes.
Current standard-of-care therapies have transformed the treatment of wet AMD by primarily inhibiting vascular endothelial growth factor A (VEGF-A), a member of the VEGF signalling pathway which contributes to the pathophysiology of retinal diseases, including wet AMD.
The VEGF-C and VEGF-D signaling pathways are also important in the pathogenesis of retinal diseases, and evidence shows they are upregulated following VEGF-A suppression. Blocking VEGF-A alone therefore may contribute to an incomplete response.
Sozinibercept is a novel, first-in-class VEGF-C/D ‘trap’ inhibitor designed to be used in combination with standard-of-care anti-VEGF-A therapies, with the potential to deliver superior visual outcomes.